Skip to main content

Table 5 Clinical and economic outcomes for CAZ-AVI sequence vs. Meropenem sequence, discounted by 3%

From: Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

OutcomesCAZ-AVI SequenceaMeropenem Sequenceb
% of patients with cure92.98%90.24%
% of patients died in hospital5.04%5.68%
% of patients with AE6.14%5.74%
Average days in hospital12.9414.18
LYs4.4104.381
QALYs4.0193.960
Drug costs€ 2943€ 818
Hospitalisation costs€ 11,262€ 12,453
SAE costs€ 186€ 174
Recurrence costs€ 0€ 22
Total costs€ 14,391€ 13,467
Incremental cost per QALY gained€ 15,574
  1. AE = adverse event; CAZ-AVI = ceftazidime-avibactam; LY = life year; QALY = quality-adjusted life year; SAE = serious adverse event.
  2. aCAZ-AVI plus metronidazole, followed by colistin + tigecycline + high-dose meropenem
  3. bMeropenem, followed by colistin + tigecycline + high-dose meropenem